🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Australian and New Zealand lymphoma tweeps: combined Australian Lymphoma Alliance / Lymphoma Registry breakfast at #BLOOD2019 in #Perth #lymSM eventbrite.com.au/e/lymphoma-int… via Eventbrite

Kuhnl Real world CART England DLBCL • 125 pts approved, 91 had cells • most bridging chemo • disappointing results at 3mo • ORR & CRR % Axicel: 37, 21 Tisagen: 29, 17 Med EFS: 3.1mo Minority benefit. Need to develop biomarkers & be realistic discussing with pts #ASH19 #lymsm

So thrilled our front line mantle cell lymphoma trial is actively recruiting and so grateful to be working with a great mentor. @DrElizaHawkes Happy world lymphoma awareness day everyone! #lymSM #lymphoma #WLAD2020 #Womeninlymphoma

Please RT. New position open in the Laughney Lab to use single cell genomics to study inflammation and cancer. Funded by a multi-PI #R01 with Samuel Bakhoum. Great collaborative environment btw Weill Cornell Medicine and @sloan_kettering More info: laughneylab.com #sciencetwitter

I highly recommend these lectures! The first series was very engaging and educational #lymsm

Get involved in the fight against lymphoma! #lymsm

#HSANZ #COVID_19 #vaccination consensus statement for #haematology patients is out now.

We have an exciting open position for a lymphoma physician/researcher to join our heme malignancy group at Georgetown!! Please retweet/message me for more details Dr. Catherine Lai @MunshiPashna

Privileged to be part of the CAR-T team at Fiona Stanley Hospital and so grateful we can offer this world class treatment to our patients in Western Australia. Catching up for CAR-T education!! #CARTcell #lymsm #WomenInLymphoma

Great to be a member of this fantastic collaborative and inclusive alliance. 😊

What a great, clinically useful trial.

Change is coming!!...

Lisa-Cel in ASCT ineligible relapsed DLBCL 2nd line. This is the group we really need to get CAR-T in 2nd line as no curative option. • ph2, 74pts, med 74y • 26% PS 2 • ORR 80% • 75% refract or rel < 12mo • low G3+ CRS/ICANS Encouraging. #lymsm thelancet.com/journals/lanon…

Have you had lymphoma & live in a regional, rural or remote community? We want to understand your story & the challenges you have faced, to ensure that others will have access to information, specialist medical care, treatment & all the support they need surveymonkey.com/r/295JLSF

For those of you passionate about haematology education, i highly recommend sharing this brilliant & fun morphology course this with your haem trainees! Aaron Goodman - “Papa Heme” @DrElizaHawkes Erica Wood Graham Collins Michael Dickinson David Joske

CAR-T: THE PATIENT EXPERIENCE Register for our webinar on Thursday 25/8 - 4:00PM (AEST) with Dr Duncan Purtill, Fiona Stanley Hospital and Samantha Easton, RBWH. Register: lymphoma.org.au/events/car-t-u…

Great clinically useful data. After 10y low-count MBL had a significant 4.3-fold increased risk of lymphoid malignancies but no association with OS (P=0.78) but did with HC-MBL (HR=1.8;95%CI:1.1-3.1,P=0.03)

IACH welcomes you to join the 1st World Congress on Controversies in Lymphoma (COLYM), which will be held virtually October 14-15, 2022 Free Registration:colymlive.cme-congresses.com/registration/ View the Program:colymlive.cme-congresses.com/program/ Anna Sureda Mehdi Hamadani, MD Stefano Luminari, MD Judith Trotman